Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer

"The breadth of knowledge Elisabeth has gained working at Celgene, alongside her extensive clinical experience, makes her a crucial addition to our team," said Florent Gros, Co-Founder and CEO of Priothera. "We are delighted to welcome Elisabeth during this exciting time as we look to progress mocravimod, into a Phase 2b/3 study as a potential treatment for patients with Acute Myeloid Leukemia receiving hematopoietic stem cell transplantation. The study is expected to begin in 2022." "The...

DUBLIN, 25/11/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

," said . " to "

" ," said Dr. Kueenburg. "

Dr. Kueenburg brings significant drug development and medical affairs experience from her years at Celgene where she most recently served as Clinical Development Lead. At Celgene she developed deep clinical development and medical affairs expertise, providing strategic insight and overseeing the coordination of multiple clinical trials, in the area of hematology and specifically in multiple myeloma. Furthermore, Dr. Kueenburg has supported the successful global launch of Celgene's Revlimid.

Prior to her numerous roles at Celgene, Dr. Kueenburg spent more than 15 years in clinical practice and academic research specializing in oncology and hematology.

Dr. Kueenburg gained her Doctor of Medicine from the University of Vienna in Austria .

Priothera is leading the way in developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for hematological malignancies. S1P receptor modulators are known to largely reduce egress of T cells from lymphatic tissues and not being immunosuppressants, thereby allowing for inhibition of graft-versus-host-disease (GvHD) while enhancing graft-versus-leukemia benefits in patients receiving HSCT.

Headquartered in Dublin, Ireland , Priothera was founded in 2020 by an experienced team of drug development and biotech experts.

Founding investors are Fountain Healthcare Partners ( Dublin, Ireland ), funds managed by Tekla Capital Management, LLC ( Boston, Massachusetts ), HealthCap ( Stockholm, Sweden ) and EarlyBird Venture Capital ( Berlin, Germany ).

For more information please visit: www.Priothera.com

E: info@priothera.com

 

E: priothera@medistrava.com

T: +44 (0)7714 306525